scispace - formally typeset
Open AccessJournal ArticleDOI

Gout

About
This article is published in BMJ.The article was published on 2011-04-01 and is currently open access. It has received 729 citations till now.

read more

Citations
More filters
Journal ArticleDOI

Sugar-sweetened beverages and risk of obesity and type 2 diabetes: Epidemiologic evidence

TL;DR: It is thought that SSBs contribute to weight gain in part by incomplete compensation for energy at subsequent meals following intake of liquid calories, and should be replaced by healthy alternatives such as water, to reduce risk of obesity and chronic diseases.
Journal ArticleDOI

Uric acid transport and disease.

TL;DR: The biology of urate metabolism and its role in disease is discussed and recent studies identifying SLC2A9, which encodes the glucose transporter family isoform Glut9, as a major determinant of plasma uric acid levels and of gout development are identified.
Journal ArticleDOI

A Broader View: Microbial Enzymes and Their Relevance in Industries, Medicine, and Beyond

TL;DR: In this review, an approach has been made to highlight the importance of different enzymes with special emphasis on amylase and lipase in the different industrial and medical fields.
Journal ArticleDOI

Where is mTOR and what is it doing there

TL;DR: The finding that mTORC1 is localized to the lysosome has significantly enhanced the understanding of m TORC1 regulation and may be a general principle used by TOR to enact precise spatial and temporal control of cell growth.
References
More filters
Journal ArticleDOI

Prevention and treatment of the metabolic syndrome.

TL;DR: Among the more speculative benefits of treatment are improved liver function in nonalcoholic fatty liver disease and a reduction in the risk of acute gout and drugs that beneficially affect carbohydrate metabolism and delay or even prevent the onset of DM could be useful in patients with the metabolic syndrome.
Journal ArticleDOI

Allopurinol Dosing in Renal Impairment: Walking the Tightrope Between Adequate Urate Lowering and Adverse Events

TL;DR: In patients with severe disease and persistent hyperuricemia, allopurinol dose escalation above those recommended by the guidelines should be considered, with careful evaluation of the benefits and risks of therapy.
Journal ArticleDOI

Uricosuric Action of Losartan via the Inhibition of Urate Transporter 1 (URAT 1) in Hypertensive Patients

TL;DR: It is suggested thatLosartan inhibited URAT1 and thereby it lowered Sur levels in hypertensive patients, and both losartan and benzbromarone increased Cur/Ccr ratio in hypertension patients harboring the wild URAT 1 gene, regardless of the presence of hypouricemia.
Journal ArticleDOI

Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.

TL;DR: A once-daily 80-mg dose of febuxostat appears to be safe and well tolerated in different renal function groups and does not appear to require any dose adjustment based on differences in renal function.
Journal ArticleDOI

The genetic basis of hyperuricaemia and gout.

TL;DR: Genome-wide association scans for genes regulating serum urate concentrations have identified two major regulators of hyperuricaemia- the renal urate transporters SLC2A9 and ABCG2 and risk variants at each gene approximately double the risk for gout in people of Caucasian ancestry.
Related Papers (1)